Steris PLC Form 4 insider transactions

STERIS plc Director Cynthia L. Feldmann exercised stock options and sold shares, while also receiving new stock options and restricted stock units.

STERIS plc Director Richard C. Breeden received new stock options and restricted stock units as part of his compensation, some in lieu of fees.

STERIS plc Director Esther M. Alegria acquired 1,407 nonqualified stock options and 487 career restricted stock units, effective August 8, 2025.

Karen L. Burton, VP & CAO of STERIS plc, exercised stock options and sold shares on August 11, 2025.

John Adam Zangerle, STERIS plc's Senior VP, General Counsel, and Secretary, sold 1,978 ordinary shares on June 13, 2025, pursuant to a Rule 10b5-1 trading plan.

STERIS plc's Senior Vice President and CFO, Michael J. Tokich, reported the vesting of 1,141 restricted shares and the subsequent withholding of 341 shares for tax obligations on June 4, 2025.

Julia Madsen, Sr. VP and GM of Life Sciences at STERIS plc, reported the vesting of restricted shares and the subsequent disposition of a portion of these shares to cover tax obligations.

John Adam Zangerle, Senior VP, General Counsel, and Secretary of STERIS plc, disposed of 425 ordinary shares valued at $242.1 each to cover tax liabilities related to the vesting of restricted stock.

Renato Tamaro, STERIS plc's V.P. & Corporate Treasurer, reported the vesting of restricted shares and a subsequent disposition of shares to cover tax obligations on June 4, 2025.

STERIS plc's VP & CAO, Karen L. Burton, reported the disposition of 92 ordinary shares on June 4, 2025, to cover tax obligations related to the vesting of restricted stock.

Kenneth E. Kohler, Senior Vice President and General Manager of AST at STERIS plc, reported a routine disposition of 154 ordinary shares to cover tax obligations related to the vesting of restricted stock.

STERIS plc's President and CEO, Daniel A. Carestio, reported the sale of over 17,600 ordinary shares in early June 2025, following the vesting of restricted stock and tax-related withholdings.

Kenneth E. Kohler, SVP & GM of AST at STERIS plc, has reported the acquisition of 1,890 ordinary shares and 6,728 employee stock options, increasing his beneficial ownership in the company.

Renato Tamaro, STERIS plc's V.P. & Corporate Treasurer, has been granted 651 ordinary shares and 2,316 employee stock options, increasing his beneficial ownership in the company.

Cary L. Majors, SVP and President of Healthcare at STERIS plc, reported an increase in beneficial ownership through the acquisition of ordinary shares and employee stock options.

John Adam Zangerle, Senior Vice President, General Counsel, and Secretary of STERIS plc, has acquired 3,756 ordinary shares and 13,360 employee stock options as part of a compensation grant.

Julia Madsen, Senior VP and General Manager of Life Sciences at STERIS plc, reported the acquisition of 1,998 ordinary shares and 7,100 employee stock options on June 3, 2025, as part of her compensation.

STERIS plc's Senior Vice President and Chief Financial Officer, Michael J. Tokich, reported the acquisition of 2,223 ordinary shares and 7,908 employee stock options, significantly increasing his beneficial ownership in the company.

Mary Clare Fraser, SVP & Chief HRO of STERIS plc, reported the acquisition of 2,505 ordinary shares and 8,904 employee stock options on June 3, 2025, as part of her compensation, with vesting schedules extending through 2029.

STERIS plc's President and CEO, Daniel A. Carestio, has been granted 17,811 ordinary shares and 63,328 employee stock options, reinforcing his stake in the company's future performance.

Karen L. Burton, Vice President and Chief Accounting Officer of STERIS plc, has acquired 1,953 ordinary shares and 6,944 employee stock options, as reported in a recent SEC Form 4 filing.

John Adam Zangerle, Senior VP, General Counsel, and Secretary of STERIS plc, reported the disposition of 844 ordinary shares to cover tax obligations related to the vesting of restricted stock awards on June 2, 2025.

STERIS plc's Senior Vice President and CFO, Michael J. Tokich, reported the disposition of 727 ordinary shares to cover tax withholdings related to the vesting of restricted stock awards.

Renato Tamaro, VP & Corporate Treasurer of STERIS plc, reported the disposition of 165 ordinary shares to cover tax withholdings upon the vesting of restricted stock awards.

Cary L. Majors, SVP and President of Healthcare at STERIS plc, reported the vesting of restricted shares and a subsequent tax-related disposition of 564 ordinary shares at $242.08 per share.

Julia Madsen, STERIS plc's Sr. VP and GM of Life Sciences, reported the disposition of 463 ordinary shares to cover tax obligations related to the vesting of restricted stock awards.

A recent SEC Form 4 filing by STERIS plc's SVP & GM, AST, Kenneth E. Kohler, details the vesting of restricted stock, shares withheld for tax obligations, and a correction to previously reported beneficial ownership figures.

Mary Clare Fraser, SVP & Chief HRO of STERIS plc, reported the vesting of restricted shares and the subsequent withholding of shares for tax obligations, a standard insider transaction.

STERIS plc's President and CEO, Daniel A. Carestio, reported the disposition of 3,065 ordinary shares valued at $242.08 per share on June 2, 2025, to cover tax withholding obligations related to vested restricted stock awards.

Karen L. Burton, VP & CAO of STERIS plc, reported the disposition of 229 ordinary shares on June 2, 2025, solely to cover tax withholding obligations related to the vesting of restricted stock units.